Working...
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT02858921
Brief Title: Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma (NeoTrio)

First Submitted : July 16, 2016
First Submitted that Met QC Criteria : August 5, 2016
First Posted : August 8, 2016 (Estimate)

Last Update Submitted that Met QC Criteria : April 25, 2019
Last Update Posted : April 26, 2019